Amylyx Pharmaceuticals, Inc.

Listed Company

AMLXCIK 0001658551NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

Net Income

$-144.74M

Total Assets

$332.64M

Equity

$305.26M

Shares Out

111.19M

Op. Cash Flow

$-123.34M

AMLX$17.75+114.57% · past yearDBEQ Basic

Daily closing prices

Business

Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for endocrine and neurodegenerative diseases with high unmet medical needs. Its lead candidate, avexitide, is a first-in-class GLP-1 receptor antagonist in Phase 3 trials for post-bariatric hypoglycemia and congenital hyperinsulinism. The company also advances AMX0035 (a fixed-dose combination for Wolfram syndrome), AMX0114 (an antisense oligonucleotide for ALS), and AMX0318 (a long-acting GLP-1 antagonist for rare diseases). Amylyx operates in the U.S., EU, and other jurisdictions, relying on contract manufacturing organizations for production and pursuing regulatory approvals from the FDA and EMA.

Summary from 10-K filed 2026-03-03

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Product revenue, net	0	87	381	22	—
Cost of sales	0	6	25	3	—
Cost of sales - inventory impairment and loss on firm purchase commitments	0	119	—	—	—
Acquired in-process research and development	0	36	—	—	—
Research and development	90	104	128	93	44
Selling, general and administrative	63	114	188	127	39
Restructuring expenses	0	23	—	—	—
Total operating expenses	153	402	342	224	83
Loss from operations	−153	−315	39	−201	−83
Interest income	9	14	16	4	36,000
Other expense, net	−700,000	−1	−660,000	−551,000	−51,000
Total other income, net	9	13	15	4	−5
Loss before income taxes	−145	−302	54	−198	−88
Provision (benefit) for income taxes	46,000	−393,000	5	774,000	—
Net loss	−145	−302	49	−198	−88
Net loss per share - basic	−1.53	−4.43	0.73	−3.39	−13.35
Net loss per share - diluted	−1.53	−4.43	0.7	−3.39	−13.35
Weighted-average shares used in computing net loss per share - basic	95	68	67	58	7
Weighted-average shares used in computing net loss per share - diluted	95	68	70	58	7

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2024 2024-08-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Cash and cash equivalents	227	77	—	170	63
Marketable securities	90	99	—	201	—
Accounts receivable, net	88,000	447,000	—	40	15
Prepaid expenses and other current assets	7	12	—	15	10
Total current assets	324	189	—	465	382
Property and equipment, net	310,000	961,000	—	3	3
Restricted cash equivalents	985,000	1	—	719,000	700,000
Operating lease right-of-use assets	5	2	5	4	6
Deposits and other assets	2	24,000	—	—	—
Total assets	333	194	—	517	391
Accounts payable	4	3	—	22	6
Accrued expenses	18	24	—	58	38
Operating lease liabilities, current portion	1	2	—	2	2
Total current liabilities	23	28	—	82	47
Operating lease liabilities, net of current portion	5	463,000	—	2	4
Total liabilities	27	29	—	84	51
Commitments and contingencies (Note 16)	—	—	—	—	—
Common stock, $0.0001 par value; 300,000,000 shares authorized; 109,884,502 and 68,629,738 shares issued and outstanding as of December 31, 2025 and 2024, respectively	11,000	7,000	—	7,000	7,000
Additional paid-in capital	1,056	772	—	738	695
Accumulated deficit	−751	−607	—	−305	−354
Accumulated other comprehensive income (loss)	404,000	−92,000	—	197,000	−86,000
Total stockholders' equity	305	165	—	433	341
Total liabilities and stockholders' equity	333	194	—	517	391

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−145	−302	49	−198	−88
Stock-based compensation expense	28	33	37	22	3
Depreciation expense	525,000	904,000	1	487,000	52,000
Accretion of investment discounts, net	−6	−10	−10	−2	121,000
Charge for purchase of IPR&D assets	—	36	—	—	—
Other non-cash items	−169,000	958,000	—	—	—
Accounts receivable, net	359,000	40	−25	−15	—
Inventories	—	−9	−73	−10	—
Interest receivable	24,000	359,000	23,000	487,000	−144,000
Prepaid expenses and other current assets	6	2	−3	−5	−4
Operating lease right-of-use assets	2	2	2	2	—
Deposits and other assets	−2	677,000	—	—	—
Accounts payable	580,000	−19	16	2	670,000
Accrued expenses	−7	−60	22	—	—
Operating lease liabilities	−1	−2	−2	−917,000	—
Net cash used in operating activities	−123	−168	12	−180	−75
Purchases of property and equipment	−138,000	−157,000	−1	−3	−353,000
Purchases of IPR&D assets, including transaction costs	—	−36	—	—	—
Purchases of investments	−232	−232	−301	−416	−49
Proceeds from maturities of marketable securities	246	344	394	179	3
Net cash provided by investing activities	14	76	92	−239	−46
Proceeds from financings, net of issuance costs	256	—	—	—	12
Proceeds from exercise of stock options and RSUs vesting	4	2	7	—	—
Withholding taxes paid on stock-based awards	−3	−2	−3	—	—
Net cash provided by financing activities	257	348,000	4	432	159
Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents	1	−438,000	160,000	−65,000	13,000
Net increase (decrease) increase in cash, cash equivalents and restricted cash equivalents	149	−92	108	13	37
Other assets included in accounts payable and accrued expenses	500,000	—	—	—	—
Right-of-use assets obtained in exchange for new operating lease liabilities	5	—	—	5	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Amylyx Pharmaceuticals, Inc.'s CIK number?

Amylyx Pharmaceuticals, Inc.'s SEC CIK number is 0001658551 (1658551). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Amylyx Pharmaceuticals, Inc.'s SEC filings?

All of Amylyx Pharmaceuticals, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Amylyx Pharmaceuticals, Inc. last report earnings?

Amylyx Pharmaceuticals, Inc. (AMLX) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-210286). This is Amylyx Pharmaceuticals, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Amylyx Pharmaceuticals, Inc.'s most recent earnings 8-K?

Amylyx Pharmaceuticals, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001193125-26-210286. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Amylyx Pharmaceuticals, Inc.'s latest earnings 8-K →
Look up any company's CIK number →